Skip to main content
Premium Trial:

Request an Annual Quote

MDRNA Regains Compliance with Nasdaq's Minimum Bid Requirement

Premium

MDRNA announced this week that it has received notification from the Nasdaq Stock Market that its shares have regained compliance with the exchange's $1 minimum bid requirement for continued listing.

"We are pleased to have regained compliance with Nasdaq's Minimum Bid Price Requirement and believe it reflects the great progress we have made in restructuring and re-launching MDRNA as a premier RNAi drug discovery company," MDRNA President and CEO Michael French said in a statement.

MDRNA, however, still has yet to meet the Nasdaq's listing requirement of a minimum of $10 million in stockholders' equity. The company said earlier this month that it presented a plan to regain compliance to the Nasdaq's listing qualifications panel in April and expects to receive the panel's response by the end of the month.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.